Investigator Sponsored Research (ISR)
Investigator Sponsored Research (ISR) supports independent investigators and organizations conducting studies to advance knowledge of products, diseases, medical conditions, and technologies and improve treatments.
This grant was recently updated
Japan clinical applications shift from October 1–November 30, 2025 to October 1–November 30, 2026, replacing the separate January 16–March 31, 2026 Izervay round. Xtandi is removed from eligible clinical products, Izervay joins the main round, and research priorities, decision dates and the application portal also change.
Funder: Astellas
Due Dates: October 1, 2026 (Japan clinical applications open) | November 30, 2026 (Japan clinical deadline) | Rolling (Japan product-material requests)
Funding Amounts: Funding or product material; Japan generally provides funding only for clinical research and material only for nonclinical research
Summary: Supports independently sponsored research advancing knowledge of products, diseases, medical conditions, and technologies.
Key Information: The investigator or organization remains the independent sponsor, responsible for study design, conduct, analysis, and dissemination.
Description
Astellas’s Investigator Sponsored Research (ISR) program supports unsolicited, independent studies that advance medical and scientific knowledge and innovation. Areas of interest identify compounds with open programs and help investigators assess fit with Astellas’s research priorities. Alignment with these interests does not guarantee support.
In Japan, the program supports clinical and nonclinical research using Astellas medicines to establish better treatments. Clinical studies generally must follow indications, administration, and doses approved in Japan. Nonclinical proposals may investigate activity in new diseases, prioritizing diseases without treatment options or inadequately served by existing medicines. The independent sponsor retains legal and ethical responsibility for the research, including safety, and holds any required investigational new drug application or equivalent.
